http://purl.org/np/RAivQ0I4fCI7LYldHMJI9YARlNFRJeIp9ZDFdIb65eJcs
.trig | .trig.txt | .jelly | .jelly.txt
@prefix orcid: <https://orcid.org/> . @prefix this: <http://purl.org/np/RAivQ0I4fCI7LYldHMJI9YARlNFRJeIp9ZDFdIb65eJcs> . @prefix sub: <http://purl.org/np/RAivQ0I4fCI7LYldHMJI9YARlNFRJeIp9ZDFdIb65eJcs#> . @prefix np: <http://www.nanopub.org/nschema#> . @prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix ns2: <http://twoc-nlp-database-server-1:8555/solr/triples/select?fl=TRIPLE_UID,%20CORD_UID,%20SUBJECT,%20PREDICATE,%20WORDNET_SEMREL,%20%20OBJECT,%20PRED_POSITION,%20SUBJECT_CUIS,%20OBJECT_CUIS,%20UMLS_SEMREL,%20PRED_POSITION,%20PREDICATE-LEMMA&q=CORD_UID:6bnj8pcp&rows=> . @prefix ns1: <http://wordnet-rdf.princeton.edu/lemma/> . @prefix prov: <http://www.w3.org/ns/prov#> . @prefix ns3: <http://twoc-nlp-database-server-1:8555/solr/triples/select?q=TRIPLE_UID:> . @prefix npx: <http://purl.org/nanopub/x/> . sub:Head { this: a np:Nanopublication; np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo . } sub:assertion { <https://uts.nlm.nih.gov/uts/umls/concept/C1512714> ns1:compare <https://uts.nlm.nih.gov/uts/umls/concept/C0439044> . } sub:provenance { sub:assertion prov:generatedAtTime "2021-12-16T19:34:18.161242"^^xsd:dateTime; prov:wasGeneratedBy "S&T TWOC project version 2" . sub:version prov:value "2"^^xsd:integer . rdf:OBJECT rdfs:label "with lenalidomide and dexamethasone alone ( Rd )" . rdf:OBJECT-POSITION rdfs:label "35"^^xsd:integer . rdf:PREDICATE rdfs:label "compared" . rdf:PREDICATE-POSITION rdfs:label "[221]" . rdf:SUBJECT rdfs:label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" . rdf:SUBJECT-POSITION rdfs:label "102"^^xsd:integer . rdfs:ABSTRACT-UID ns2:50 "6bnj8pcp" . rdfs:SENTENCE rdfs:label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." . rdfs:TRIPLE-UID ns3:6bnj8pcp-TRIPLE-ABSTRACT-5 "6bnj8pcp-TRIPLE-ABSTRACT-5" . <https://uts.nlm.nih.gov/uts/umls/concept/C0439044> rdfs:label "alone" . <https://uts.nlm.nih.gov/uts/umls/concept/C1512714> rdfs:label "ineligible" . } sub:pubInfo { sub:assertion prov:wasDerivedFrom <https://doi.org/10.1200/jco.20.01849> . sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB"; npx:hasSignature "gUQV4nkV1MGceR/+TjLuoVdwC4yWp5hQU8DnwAjMXy1LUKDpr3C/nsc0Oix9gx1szIfFDfAuYj1mV9Ko9s4M6DWrUtUFEIpLd9dyDI3ix6TlT55PjKa8jERfIN4fMeCPuQQudCjmv4CejFS4pjDeFEhTuD4xNMlgdWtmbWLc3pY="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-12-16T19:34:18.161242"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-8954-0470 . }